BromSite® (bromfenac)
Post-operative inflammation and pain following cataract surgery
ApprovedCommercial
Key Facts
Indication
Post-operative inflammation and pain following cataract surgery
Phase
Approved
Status
Commercial
Company
About SPARC
SPARC is a specialized research and development arm that emerged from Sun Pharmaceutical Industries, concentrating on innovative drug delivery technologies and new molecular entities. The company has built a pipeline of novel formulations and new chemical entities targeting complex therapeutic areas with high unmet medical needs. Its strategic focus includes developing non-infringing, patent-protected products that offer significant clinical advantages over existing treatments. SPARC's valuation reflects its potential to deliver breakthrough innovations through its research platforms.
View full company profile